24 stories mentioning CIUpdated 2d ago
Every FINWIRES story that references CI, newest first.
Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.21, Change: $-6.37, Percent Change: -2.19%
Cigna (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.55, Change: $-6.03, Percent Change: -2.08%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $330 from $320, based on a 10.9x multiple of our 2026 EPS estimate, near CI's five-year historical forward average of 11.2x. We think CI's multiple balances pharmaceutical business momentum in CI's Evernorth segment and a timely portfolio shift toward more commercial exposure, offset by near-term challenges around higher medical costs across the managed care space. We raise our 2026 EPS estimate by $0.01 to $30.35 and lower 2027's by $0.09 to $33.42. Following Q1 results that beat consensus views, CI's annual Medical Care Ratio (MCR) guidance was maintained at 83.7% to 84.7% for 2026, suggesting cost discipline within a challenging operating environment for managed care. The company plans to exit the Individual ACA Exchange market by year-end 2026, citing the relatively small exposure relative to other parts of CI's portfolio and challenges with meaningfully scaling operations.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.
Showing 21-24 of 24
